Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Evidence Based Review CHF

2,014 views

Published on

1-hour resident-level presentation on CHF 2005

  • very nice
    can i have copy ?
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

Evidence Based Review CHF

  1. 1. An Evidence-Based Review: Congestive Heart Failure Mike Mendoza, MD, MPH Chief Resident Department of Family and Community Medicine
  2. 2. Overview <ul><li>Pathophysiology </li></ul><ul><li>Diagnosis of CHF </li></ul><ul><li>ACC / AHA Reclassification of CHF </li></ul><ul><li>Pharmacologic Treatments </li></ul><ul><li>Diastolic Heart Failure </li></ul>
  3. 3. The Syndrome of Heart Failure
  4. 4. It’s Not Just About Diuresis and Digoxin Anymore, Toto! <ul><li>Long-term reduction of circulating volume and improvement of cardiac function alone do not prevent progression of disease. </li></ul><ul><li>Treatment focused only on diuresis and inotropy is insufficient. </li></ul>
  5. 5. The “Neurohumoral” Effect <ul><li>Plays a role in compensatory mechanisms resulting from the initial cardiac insult. </li></ul><ul><ul><li>Sympathetic Nervous System </li></ul></ul><ul><ul><li>Renin-Angiotensin System </li></ul></ul><ul><li>Successful treatment of heart failure must account for these neurohumoral processes. </li></ul>
  6. 6. Sympathetic Nervous System <ul><li>Adaptive mechanism if you are being consumed by a dinosaur. </li></ul><ul><li>Counterproductive in heart failure. </li></ul><ul><ul><li>Sodium (i.e., volume) retention </li></ul></ul><ul><ul><li>Increased peripheral resistance through vasoconstriction </li></ul></ul><ul><ul><li>Increased release and decreased reuptake of NE </li></ul></ul>
  7. 7. Circulating Evil Humours <ul><li>In a series of patients with stable CHF treated with digoxin but NOT diuretics, ACE-Is or beta-blockers… </li></ul>
  8. 8. Increases in NE are Bad <ul><li>Increases in circulating norepinephrine confer worse prognosis. </li></ul><ul><li>ValHeFT Study </li></ul>
  9. 9. Renin-Angiotensin-Aldosterone
  10. 10. The Role of Remodeling <ul><li>Ventricular remodeling results in decline of overall pump function of the heart </li></ul><ul><li>Trials aimed at reducing remodeling showed a return normal ventricular size and shape. </li></ul>
  11. 11. Remodeling <ul><li>The SOLVD study demonstrated that enalapril significantly improved clinical course of patients with LVSD. </li></ul><ul><li>The SOLVD-Echo Substudy sought to determine the basis for this improvement. </li></ul><ul><li>A subset of the original patients in the treatment and placebo groups underwent TTE. </li></ul>
  12. 12. Clinical Diagnosis of CHF <ul><li>Can be difficult based on history and exam alone. </li></ul><ul><li>Cross-sectional study of 259 patients thought to have CHF by conventional clinical criteria underwent TTE. </li></ul><ul><li>Clinical findings then correlated to presence of LVSD (LVEF < 25%) on echo. </li></ul><ul><li>Only 16% of patients suspected to have CHF had LVSD on echo. </li></ul><ul><li>Addition of electrocardiogram (ECG) assists in making diagnosis. </li></ul>
  13. 13. Clinical Diagnosis of CHF 89% Displaced Apex + Hx of MI - 0.03 + 4.2 + 6.0 + 8.5 + 16.5 + 24.0 Likelihood Ratio Absence of DOE Hx of MI Hx of DM2 64% JVD 75% Displaced Cardiac Apex 77% S3 gallop PPV Exam Finding
  14. 14. New York Heart Association Symptoms at rest. Class 4 Marked limitation of activity; comfortable only at rest. Class 3 Slight, mild limitation of activities; comfortable with rest or with mild exertion. Class 2 No limitation of activities; asymptomatic from ordinary activities. Class 1
  15. 15. ACC/AHA Classification of CHF Refractory symptoms requiring special intervention Stage D Structural heart disease, previous or currently symptomatic Stage C Structural heart disease, asymptomatic Stage B At high risk for the development of heart failure but have no apparent structural abnormality of the heart Stage A
  16. 16. Why the Reclassification? <ul><li>NYHA classification </li></ul><ul><ul><li>A functional classification only; you could be reclassified based on your response to medication </li></ul></ul><ul><ul><li>No emphasis on risk factors and modification </li></ul></ul><ul><li>ACC/AHA classification </li></ul><ul><ul><li>Underscores progressive nature of CHF </li></ul></ul><ul><ul><li>Emphasizes identification of risk factors and risk factor modification </li></ul></ul><ul><ul><li>Link Stage of CHF to Treatment Recommendations </li></ul></ul>
  17. 17. ACC/AHA Treatment Recommendations
  18. 18. STAGE A <ul><li>Treating hypertension reduces the prevalence of LVH and CHF. </li></ul><ul><li>A retrospective cohort study of 10,333 participants in the Framingham study, aged 45 to 74 years old, conducted from 1950-1989 </li></ul><ul><ul><li>Age-adjusted prevalence of SBP > 160 or DBP > 100 declined from </li></ul></ul><ul><ul><ul><li>18.5% to 9.2% in men and </li></ul></ul></ul><ul><ul><ul><li>28.0% to 7.7% among women </li></ul></ul></ul><ul><ul><li>Age-adjusted prevalence of LVH (on ECG) declined from </li></ul></ul><ul><ul><ul><li>4.5 percent to 2.5% among men and </li></ul></ul></ul><ul><ul><ul><li>3.6% to 1.1% among women </li></ul></ul></ul><ul><li>Over this period, incidence of heart failure has decreased 30 to 50% </li></ul>
  19. 19. Anti-Hypertensive Therapy <ul><li>Goal diastolic BP in patients with DM2 < 80. </li></ul><ul><li>Treatment with ACE-inhibitor even in absence of symptoms reduces rates of death, MI and stroke. </li></ul><ul><ul><li>Type 2 Diabetics especially at risk. </li></ul></ul><ul><ul><li>UKPDS: an RCT of 1148 patients randomized to tight or less tight BP control </li></ul></ul><ul><ul><li>Significant reduction in the risk of death related to diabetes, diabetic nephropathy, diabetic retinopathy. </li></ul></ul><ul><ul><li>ACE-I or beta-blocker equally effective for these endpoints. </li></ul></ul><ul><li>Prevent remodeling. </li></ul>
  20. 20. STAGE B <ul><li>Structural heart disease is present, but asymptomatic </li></ul><ul><li>Continue to address risk factors </li></ul><ul><ul><li>Moderate sodium restriction </li></ul></ul><ul><ul><li>Weight monitoring </li></ul></ul><ul><ul><li>Moderation of EtOH, avoidance of NSAIDs </li></ul></ul><ul><li>ACE-inhibitors or ARBs in all patients; beta-blockers in selected patients </li></ul>
  21. 21. ACE Inhibitors <ul><li>Decrease the conversion of angiotensin I to angiotensin II, thus minimizing the physiologic effects of angiotensin II on the heart, vasculature, and renal blood flow. </li></ul><ul><li>A meta-analysis of all RCTs of ACE-inhibitors showed a statistically significant reduction in total mortality (OR, 0.77) and in combined endpoint of mortality or hospitalization (OR, 0.65). </li></ul><ul><ul><li>Similar effects for all ACE-Is studied. </li></ul></ul><ul><ul><li>Patients with the lowest EF had the greatest benefit, usually in the first 3 months of treatment. </li></ul></ul><ul><li>CONSENSUS trial showed that one-year mortality reduced from 52% to 36% for NYHA Class IV patients. </li></ul>
  22. 22. Beta Blockers <ul><li>Blunt the sympathetic nervous system, slow HR, decrease blood pressure. Also thought to have a direct effect on reversing remodeling. </li></ul><ul><li>Reported reduction in mortality is 34 to 65% with NNT 14 to 26. </li></ul><ul><li>Most widely studied: metoprolol, carvedilol, and bisoprolol. </li></ul><ul><li>Most patients enrolled in these studies had NYHA Class II or worse CHF. </li></ul>
  23. 23. Beta Blockers (cont’d) <ul><li>Metoprolol </li></ul><ul><ul><li>MERIT-HF </li></ul></ul><ul><ul><li>3991 patients with NYHA Class II – IV CHF and EF < 40% randomized to metoprolol or placebo, with target metoprolol dose of 200mg daily. </li></ul></ul><ul><ul><li>Study stopped early after one year when all-cause mortality was lower in the metoprolol group vs. placebo group. </li></ul></ul><ul><ul><li>Overall reduction in mortality (RR 0.66). </li></ul></ul>
  24. 24. Beta Blockers (cont’d) <ul><li>Carvedilol </li></ul><ul><ul><li>COPERNICUS Trial </li></ul></ul><ul><ul><li>A study of 2289 patients with severe HF, EF < 25%, randomized to carvedilol or placebo in addition to usual care. </li></ul></ul><ul><ul><li>35% decrease in the risk of death in carvedilol group </li></ul></ul><ul><ul><li>24% decrease in the combined risk of death or hospitalization </li></ul></ul>
  25. 25. Angiotensin Receptor Blockers <ul><li>ARBs also interfere with the renin-angiogensin-aldosterone system </li></ul><ul><li>A Cochrane meta-analysis of 17 RCTs comparing ARBs to ACE-Is in patients with NYHA Class II – IV CHF </li></ul><ul><ul><li>ARBs and ACE-Is are equivalent for all-cause mortality </li></ul></ul><ul><ul><li>Small reduction in rate of hospitalization for the combination of ARB + ACE over ACE alone (OR, 0.74) </li></ul></ul><ul><ul><li>A good option for people who cannot tolerate ACE-Is </li></ul></ul>
  26. 26. Angiotensin Receptor Blockers
  27. 27. STAGE C <ul><li>Symptomatic from structural heart disease. </li></ul><ul><li>ACE-Is and beta-blockers in all patients </li></ul><ul><li>Consider digoxin, diuretics and revascularization. </li></ul>
  28. 28. Digoxin <ul><li>Digitalis Investigation Group (“DIG”) </li></ul><ul><ul><li>Overall survival is not improved with digoxin. </li></ul></ul><ul><ul><li>Rate of hospitalization is improved, particularly those with EF < 25%, dilated cardiomyopathy, and NYHA III or IV. </li></ul></ul><ul><ul><li>Improves exercise tolerance and decreases symptoms. </li></ul></ul><ul><li>Cochrane review of 20 RCTs in 2004 agreed with the above. </li></ul>
  29. 29. Spironolactone <ul><li>A potassium-sparing diuretic that antagonizes aldosterone at the DCT and causes water excretion and potassium retention. </li></ul><ul><li>RALES Trial </li></ul><ul><ul><li>1663 NYHA Class IV patients already on ACE-I and loop diuretic. 70% of patients also on digoxin. Only 10% taking beta-blockers. </li></ul></ul><ul><ul><li>Randomized to addition of placebo or spironolactone 25 titrated upward. </li></ul></ul><ul><ul><li>30% reduction in death in treatment group. NNT=9. </li></ul></ul>
  30. 30. Diuretics <ul><li>Loop diuretics (e.g., furosemide) relieve symptoms but do not slow progression of underlying disease. </li></ul><ul><li>Loop diuretics preferable to thiazides. </li></ul>
  31. 31. Diastolic Heart Failure <ul><li>Refers to an abnormality of diastolic distensibility, filling or relaxing of the LV. </li></ul><ul><li>One-third of all patients with CHF. </li></ul><ul><li>Etiologies: hypertrophic, scarring from ischemic disease, infiltrative diseases </li></ul><ul><li>Diagnosis requires Echo with EF > 40% and no evidence of acute valvular disease or pericarditis. </li></ul>
  32. 32. Diastolic Heart Failure
  33. 33. Management of Diastolic HF <ul><li>Initial Management </li></ul><ul><ul><li>Diuretics </li></ul></ul><ul><ul><li>Rate control </li></ul></ul><ul><li>Long-term Management </li></ul><ul><ul><li>RCTs of any one agent are generally lacking. </li></ul></ul><ul><ul><li>In one RCT of NYHA II, III or IV comparing candesartan (ARB) to placebo, treatment was associated with fewer hospitalizations, and a non-significant trend toward reducing death. </li></ul></ul>

×